222 related articles for article (PubMed ID: 22442308)
1. Therapeutic significance of estrogen receptor β agonists in gliomas.
Sareddy GR; Nair BC; Gonugunta VK; Zhang QG; Brenner A; Brann DW; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2012 May; 11(5):1174-82. PubMed ID: 22442308
[TBL] [Abstract][Full Text] [Related]
2. Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells.
Sareddy GR; Pratap UP; Venkata PP; Zhou M; Alejo S; Viswanadhapalli S; Tekmal RR; Brenner AJ; Vadlamudi RK
Stem Cells; 2021 May; 39(5):536-550. PubMed ID: 33470499
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Liu X; Wang L; Chen J; Ling Q; Wang H; Li S; Li L; Yang S; Xia M; Jing L
Mol Med Rep; 2015 Feb; 11(2):1516-22. PubMed ID: 25351348
[TBL] [Abstract][Full Text] [Related]
4. Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells.
Schüler-Toprak S; Moehle C; Skrzypczak M; Ortmann O; Treeck O
BMC Cancer; 2017 May; 17(1):319. PubMed ID: 28482871
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
[TBL] [Abstract][Full Text] [Related]
6. Highly selective salicylketoxime-based estrogen receptor β agonists display antiproliferative activities in a glioma model.
Paterni I; Bertini S; Granchi C; Tuccinardi T; Macchia M; Martinelli A; Caligiuri I; Toffoli G; Rizzolio F; Carlson KE; Katzenellenbogen BS; Katzenellenbogen JA; Minutolo F
J Med Chem; 2015 Feb; 58(3):1184-94. PubMed ID: 25559213
[TBL] [Abstract][Full Text] [Related]
7. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist.
Mersereau JE; Levy N; Staub RE; Baggett S; Zogovic T; Chow S; Ricke WA; Tagliaferri M; Cohen I; Bjeldanes LF; Leitman DC
Mol Cell Endocrinol; 2008 Feb; 283(1-2):49-57. PubMed ID: 18177995
[TBL] [Abstract][Full Text] [Related]
8. Update on the therapeutic significance of estrogen receptor beta in malignant gliomas.
Lan YL; Zou S; Wang X; Lou JC; Xing JS; Yu M; Zhang B
Oncotarget; 2017 Oct; 8(46):81686-81696. PubMed ID: 29113424
[TBL] [Abstract][Full Text] [Related]
9. The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth.
Liang Y; Besch-Williford C; Hyder SM
Breast Cancer Res Treat; 2022 Feb; 192(1):53-63. PubMed ID: 35037188
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor β agonists affect growth and gene expression of human breast cancer cell lines.
Lattrich C; Stegerer A; Häring J; Schüler S; Ortmann O; Treeck O
Steroids; 2013 Feb; 78(2):195-202. PubMed ID: 23153457
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
Hinsche O; Girgert R; Emons G; Gründker C
Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation and modulation of interaction of estrogen receptors with coregulators induced by ERα and ERβ agonists.
Evers NM; van den Berg JH; Wang S; Melchers D; Houtman R; de Haan LH; Ederveen AG; Groten JP; Rietjens IM
J Steroid Biochem Mol Biol; 2014 Sep; 143():376-85. PubMed ID: 24923734
[TBL] [Abstract][Full Text] [Related]
13. Preferential estrogen receptor β ligands reduce Bcl-2 expression in hormone-resistant breast cancer cells to increase autophagy.
Ruddy SC; Lau R; Cabrita MA; McGregor C; McKay BC; Murphy LC; Wright JS; Durst T; Pratt MA
Mol Cancer Ther; 2014 Jul; 13(7):1882-93. PubMed ID: 24785256
[TBL] [Abstract][Full Text] [Related]
14. Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Sareddy GR; Li X; Liu J; Viswanadhapalli S; Garcia L; Gruslova A; Cavazos D; Garcia M; Strom AM; Gustafsson JA; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2016 Apr; 6():24185. PubMed ID: 27126081
[TBL] [Abstract][Full Text] [Related]
15. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
16. Cancer therapy using natural ligands that target estrogen receptor beta.
Sareddy GR; Vadlamudi RK
Chin J Nat Med; 2015 Nov; 13(11):801-807. PubMed ID: 26614454
[TBL] [Abstract][Full Text] [Related]
17. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells.
Williams C; Edvardsson K; Lewandowski SA; Ström A; Gustafsson JA
Oncogene; 2008 Feb; 27(7):1019-32. PubMed ID: 17700529
[TBL] [Abstract][Full Text] [Related]
18. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
Cotrim CZ; Fabris V; Doria ML; Lindberg K; Gustafsson JÅ; Amado F; Lanari C; Helguero LA
Oncogene; 2013 May; 32(19):2390-402. PubMed ID: 22751110
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor beta: an overview and update.
Zhao C; Dahlman-Wright K; Gustafsson JA
Nucl Recept Signal; 2008 Feb; 6():e003. PubMed ID: 18301783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]